Does 22q13 deletion / Phelan-McDermid Syndrome have a cure?

Currently, there is no medical cure for 22q13 deletion syndrome, also known as Phelan-McDermid Syndrome, as it is a genetic condition involving the loss of the SHANK3 gene. While a cure is not yet available, current clinical management focuses on multidisciplinary support to improve quality of life, and international research is rapidly advancing toward precision therapies that target the underlying molecular pathways of Phelan-McDermid Syndrome.

What is the current approach to managing Phelan-McDermid Syndrome?

Since no curative treatment exists for 22q13 deletion syndrome, clinical care is centered on symptom management and developmental support. Because Phelan-McDermid Syndrome impacts multiple systems, care is usually coordinated by a team including neurologists, speech therapists, physical therapists, and behavioral specialists. Treatments are designed to address specific manifestations, such as anti-seizure medication for epilepsy, behavioral therapies for autism spectrum disorder-related symptoms, and occupational therapy to address sensory processing challenges. At DiseaseMaps.org, 35 community members have shared their experiences, highlighting how early intervention and personalized support plans significantly improve functional outcomes for individuals living with Phelan-McDermid Syndrome.

What promising research directions are currently being explored?

Research into 22q13 deletion syndrome has accelerated significantly due to a deeper understanding of the SHANK3 gene's role in synaptic function. Scientists are investigating how to restore or compensate for the loss of SHANK3 protein in the brain. Current research avenues include:

• Pharmacological interventions: Trials are testing compounds that may improve synaptic plasticity and neurotransmitter balance, specifically targeting the signaling pathways disrupted in Phelan-McDermid Syndrome.


• Gene modulation: Researchers are exploring methods to upregulate the remaining healthy copy of the SHANK3 gene to restore normal protein levels.


• Precision medicine: Using induced pluripotent stem cells (iPSCs) derived from patients with Phelan-McDermid Syndrome to screen drug candidates in a laboratory setting, allowing for more personalized treatment selection.

Are there clinical trials available for Phelan-McDermid Syndrome?

Yes, there are active clinical studies and natural history studies dedicated to 22q13 deletion syndrome. Natural history studies are particularly important because they document the progression of the condition over time, providing the baseline data necessary for regulatory agencies like the FDA to approve future therapies. While these studies do not provide a cure, participating in them is a vital way for families to contribute to the global research effort and gain access to expert clinical teams.

What is the timeline for potential breakthroughs?

While it is impossible to provide a definitive timeline for a cure, the field of neurodevelopmental research is moving faster than ever before. Many experts believe we are in a "golden age" of rare disease research. While gene replacement or widespread gene editing for Phelan-McDermid Syndrome remains in the preclinical or early investigative phase, the investment in SHANK3-related research is at an all-time high. Families should remain cautiously optimistic, as advancements in biotechnology are consistently shortening the path from laboratory discovery to clinical application.

Next steps

• Consult a specialist: Work with a geneticist or neurologist familiar with Phelan-McDermid Syndrome to ensure your child has a comprehensive, up-to-date care plan.


• Join the community: Connect with the 35+ members on DiseaseMaps.org to share resources, clinical experiences, and emotional support.


• Register for research: Enroll in the Phelan-McDermid Syndrome International Registry to stay informed about recruitment for upcoming clinical trials.


• Stay informed: Follow updates from the Phelan-McDermid Syndrome Foundation (PMSF) for the most reliable research news.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Phelan-McDermid Syndrome Overview.


• Orphanet: 22q13.3 deletion syndrome (Phelan-McDermid Syndrome) reference portal.


• Phelan-McDermid Syndrome Foundation (PMSF): Clinical research and family resources.


• OMIM (Online Mendelian Inheritance in Man): SHANK3 gene and 22q13.3 deletion data.